NEW YORK, Feb. 08, 2023 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
Do Stem Cell Treatments For Arthritis Work? Get the Facts.
Can stem cell treatments for arthritis bring relief to those suffering from the disease?
From the dawn of history to present day, the swelling and aching of joints rank as one of the most troublesome indicators of age. As connective tissue breaks down over time, the result is stiffening, pain and immobility. While some are luckier than others, few seem to escape it entirely – which is why stem cell treatment for arthritis is intriguing to so many. [Read more…]
The Future Forecast for MSC-Based Therapeutics
Presently, MSC-based clinical trials are being conducted for a range of disease conditions, with many completed trials showing safety and efficacy. Clinical utility of MSCs is primarily attributed to their four key biological properties, which include: [Read more…]
Athersys Provides MultiStem Clinical Update
Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma
Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke
CLEVELAND–Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions. [Read more…]
Sartorius collaborates with RoosterBio to advance downstream purification processes for the manufacture of exosomes
Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency.
FREDERICK, Md., Jan. 5, 2023 – The life science group Sartorius extended a strategic collaboration partnership agreement with RoosterBio Inc. (RoosterBio) to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 60
- Next Page »
